Newsroom
All News
- All News
- In the News
- Press Releases
- Publications
- Events
The Role of a Host Response Test in Early Identification and Appropriate Intervention for Sepsis
Dr. Roy Davis provides an overview of the current challenges of sepsis diagnosis and management, specifically related to early identification and appropriate intervention. He describes how the host immune response can be leveraged by including a gene expression assay as part of the Sepsis Clinical Toolset. The proposed role for...
SeptiCyte® RAPID in Sepsis Cases with Malignancies or Treated with Anitneoplastics/Immunosuppressants
A study showing the performance of SeptiCyte RAPID in patients with malignancies and/or on anti-neoplastic or corticosteroid therapies. IMM-009-SCCM-04-01-SC
Immunexpress Presents Data Further Demonstrating SeptiCyte® RAPID Performance at the Society of Critical Care Medicine’s 50th Annual Critical Care Congress
Data Demonstrate the Performance of SeptiCyte® RAPID is Unaltered by Patient Malignancy or Treatment with Anti-neoplastics or Immunosuppressants Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a research snapshot presentation of clinical data demonstrating the performance of SeptiCyte® RAPID in adult and pediatric...
Immunexpress to Present SeptiCyte® RAPID Performance Data at the 50th Critical Care Congress
Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the publication of an abstract for a research snapshot presentation to be presented as part of the Society of Critical Care Medicine's (SCCM) 50th Annual Critical Care Congress being held virtually Jan. 31 through Feb....
A Fully Integrated Diagnostic Test to Discriminate Sepsis from Infection-Negative Systemic Inflammation
Sepsis is a serious medical condition that manifests with a dysregulated immune response to an infection in the bloodstream, and is a major cause of morbidity and mortality worldwide. Many non-infectious conditions can lead to a state of hyper-inflammation known as the systemic inflammatory response syndrome (SIRS), which clinically can...
Molecular Dx Company Biocartis ‘At Inflection Point’ As It Eyes Infectious Disease Market
Executive Summary Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.
Immunexpress to Present SeptiCyte® RAPID Data at the Association for Molecular Pathology Annual Meeting
Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced further SeptiCyte® RAPID data demonstrating performance, reproducibility and identification of fungal infections, in two poster presentations at the Association for Molecular Pathology (AMP) 2020 Annual Meeting & Expo on Nov. 16-20. “Our SeptiCyte®...
Comparison of a Cartridge-Based Host Gene Expressions Test to a Manual Method for Use in the Diagnosis of Sepsis
SeptiCyte® RAPID test is a rapid, repeatable, reproducible, near-patient, immune-response sepsis diagnostic, providing accurate results in ~ 1 hr to differentiate sepsis from SIRS
In Silico Performance of a Rapid Sepsis Test in Patients with Candidemia
SeptiCyte® RAPID differentiated patients with candidemia from those with INSI/SIRS, not infected and healthy subjects
Immunexpress to Present SeptiCyte® RAPID Data at the Association for Molecular Pathology Annual Meeting
Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that it will present data in two posters and host a workshop at the Association for Molecular Pathology (AMP) 2020 Annual Meeting & Expo taking place virtually on Nov. 16-20, 2020. Details of...
SCCM Podcast: Severe COVID-19 and Sepsis
Severe COVID-19 infection can be a form of viral sepsis with occasionally concomitant bacterial infection. Pamela M. Peeke MD, MPH, FACP, FACSM, is joined by Russell Miller, MD, MPH, FCCM, to discuss the definition of sepsis and overlap with case descriptions of patients with severe COVID-19, how experience with viral...
Biocartis announces market release of SeptiCyte RAPID test on Idylla
Biocartis Group has released of SeptiCyte RAPID on Idylla as a CE-marked IVD test. SeptiCyte RAPID is a host-response test that distinguishes sepsis from non-infectious systemic inflammation in patients suspected of sepsis and provides actionable results in about one hour.
If you are a member of the media, please contact:
Maggie Beller
Russo Partners
(646) 942-5631
maggie.beller@russopartnersllc.com